Locametz™ (formerly Gallium (68Ga) gozetotide)

Overview: 

Locametz™ is a kit for the preparation of gallium Ga(68) gozetotide injection that was approved by the FDA in March 2022.  Locametz™ is a radioimaging agent that is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer.

Status: 

Purdue Faculty: 

Dr. Philip Low

Clinical Trial Information: 

Phase 3 Trial - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Development Partner: 

Novartis

Endocyte